Manufacturer Quantity Restrictions and Generic vs Brand Name Lenalidomide Use Among Insured Patients

This cohort study assesses patients’ use of brand-name and generic lenalidomide following the first generic market entrant in March 2022.

Authors

Institutions

Publication Details

Journal
JAMA Network Open
Published
2026-11-17
DOI
https://doi.org/10.1001/jamanetworkopen.2026.44411
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Manufacturer Quantity Restrictions and Generic vs Brand Name Lenalidomide Use Among Insured Patients

Haiden A. Huskamp, Youngmin Kwon, Stacie B. Dusetzina, Nancy Lynn Keating et al.
JAMA Network Open
Pharmaceutical Economics and Policy
article

Manufacturer Quantity Restrictions and Generic vs Brand Name Lenalidomide Use Among Insured Patients

Haiden A. Huskamp, Youngmin Kwon, Stacie B. Dusetzina, Nancy Lynn Keating, Shelley A. Jazowski, Grace Castle, Yutong (Linda) Lin
article en

Abstract

This cohort study assesses patients’ use of brand-name and generic lenalidomide following the first generic market entrant in March 2022.

JAMA Network OpenVol. 9(11)
Brigham and Women's Hospital (US), Harvard University (US), Vanderbilt University (US), Vanderbilt-Ingram Cancer Center (US), Wake Forest University Health Sciences (US), Wake Forest University (US)
Good health and well-being
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon